NEW Draft Guidelines for EGPA presented at #ACR19 @RheumNow 1. TTE and FFS to guide tx 2. GC plus cytoxan or rituxan for active/severe dx 3. Imuran/MMF/MTX for maintenance after severe dx 4. Mepo for non-severe over csDMARDs Larger role for RTX than expected, overall reasonable https://t.co/MEb10n5Mzd